Traders should monitor upcoming clinical trial announcements for TN-301 in DMD or HFpEF, as successful development could significantly revalue this pipeline asset. The differentiated preclinical profile vs. an approved therapy increases its strategic importance despite Tenaya's small market cap.
Price Chart
Executive Summary
Tenaya Therapeutics presented preclinical data showing its selective HDAC6 inhibitor TN-301 outperformed the approved DMD drug givinostat in improving muscle function and correcting cardiomyopathy drivers in DMD models. The data support advancing TN-301 into Phase 2 trials for DMD and HFpEF, with a potentially superior safety profile due to high selectivity. While promising, these are preclinical results and not yet validated in humans.
Key Facts
- TN-301 outperformed givinostat in preclinical DMD models, restoring grip strength to wild-type levels in mdx mice at 3 mg/kg, while givinostat (10 mg/kg) did not.
- TN-301 corrected calcium handling and mitochondrial dysfunction in human DMD iPSC-derived cardiomyocytes, whereas givinostat worsened these defects.
- TN-301 showed no histone acetylation changes, indicating >3,000-fold selectivity for HDAC6 over other HDACs, potentially avoiding off-target toxicities.
- Phase 1 trial in healthy adults showed TN-301 was well tolerated with no serious adverse events or dose-limiting toxicities.
- Tenaya plans to advance TN-301 into clinical studies for DMD and HFpEF, two high-unmet-need indications.
Financial Impact
No direct financial impact disclosed; potential long-term value if TN-301 succeeds in clinical development for DMD or HFpEF, large-market indications.
Risk Factors
- Preclinical results may not translate to human efficacy.
- Clinical development timelines are uncertain and funding-dependent.
- Competition from other DMD and HFpEF therapies in development.
- Recent insider selling ($1.4M in 30 days) may signal caution.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3251810 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 2d ago | DEFA14A | $0.3945 | awaiting T+60 | — | $0.4104 (+4.03%) |
Oct 23, 2026 2d ago | DEF 14A | $0.3850 | awaiting T+60 | — | $0.4104 (−6.60%) |
Aug 17, 2026 9w ago | 144 | $0.6990 | awaiting T+60 | — | $0.4104 (+41.29%) |
Jul 2, 2026 16w ago | 8-K | $0.7869 $0.5898 | ▼ −25.05% | ▼ −28.62% | $0.4104 (−47.85%) |
Jun 29, 2026 17w ago | 8-K | $0.7349 $0.6822 | ▼ −7.17% | ▼ −11.56% | $0.4104 (−44.16%) |
Jun 12, 2026 19w ago | Institutional Cluster | $0.7118 $0.6634 | ▲ +6.80% | ▲ +10.06% | $0.4104 (+42.34%) |
May 29, 2026 21w ago | 8-K | $0.8700 $0.7014 | ▼ −19.38% | ▼ −20.61% | $0.4104 (−52.83%) |
May 19, 2026 22w ago | Insider Cluster | $0.8080 $0.7281 | ▼ −9.89% | ▼ −14.89% | $0.4104 (−49.21%) |
Apr 16, 2026 27w ago | DEFA14A | $0.7470 $0.8365 | ▲ +11.98% | ▲ +4.94% | $0.4104 (−45.06%) |
Mar 11, 2026 32w ago | 8-K | $0.8930 $0.7280 | ▼ −18.48% | ▼ −29.17% | $0.4104 (−54.04%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers